Literature DB >> 2405111

Hypothermia but not the N-methyl-D-aspartate antagonist, MK-801, attenuates neuronal damage in gerbils subjected to transient global ischemia.

A Buchan1, W A Pulsinelli.   

Abstract

Several laboratories have reported a significant reduction of ischemia-induced injury to hippocampal neurons in rodents treated with competitive and noncompetitive N-methyl-D-aspartate (NMDA) receptor-channel antagonists. This study examined the effects of the noncompetitive antagonist (+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801) in Mongolian gerbils subjected to 5 min of bilateral carotid artery occlusion. In adult female gerbils, single doses of MK-801 injected 1 hr prior to ischemia significantly (p less than 0.01) reduced damage to CA1 hippocampal neurons. However, the drug rendered the postischemic animals comatose and hypothermic for several hours compared with the saline-treated animals. In subsequent experiments, animals pretreated with MK-801 and maintained normothermic during and after forebrain ischemia demonstrated no amelioration of hippocampal damage. Gerbils not treated with MK-801, but kept hypothermic in the postischemic period to approximately the same degree (34.5 degrees C) and duration (8 hr) as was induced by MK-801 therapy showed significant (p less than 0.01) protection of CA1 neurons against ischemia. The neuroprotective activity of MK-801 against transient global ischemia appears to be largely a consequence of postischemic hypothermia rather than a direct action on NMDA receptor-channels.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2405111      PMCID: PMC6570351     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  54 in total

1.  MK-801 effect on regional cerebral oxidative stress rate induced by different duration of global ischemia in gerbils.

Authors:  Vesna Selakovic; Branka Janac; Lidija Radenovic
Journal:  Mol Cell Biochem       Date:  2010-04-27       Impact factor: 3.396

2.  Therapeutic applications of hypothermia in cerebral ischaemia.

Authors:  Bruno P Meloni; Frank L Mastaglia; Neville W Knuckey
Journal:  Ther Adv Neurol Disord       Date:  2008-09       Impact factor: 6.570

Review 3.  [Controlled mild-to-moderate hypothermia in the intensive care unit].

Authors:  A Brüx; A R J Girbes; K H Polderman
Journal:  Anaesthesist       Date:  2005-03       Impact factor: 1.041

Review 4.  Clinical trials for cytoprotection in stroke.

Authors:  Lise A Labiche; James C Grotta
Journal:  NeuroRx       Date:  2004-01

Review 5.  Calcium, energy metabolism and the development of selective neuronal loss following short-term cerebral ischemia.

Authors:  N R Sims
Journal:  Metab Brain Dis       Date:  1995-09       Impact factor: 3.584

6.  Protection against post-ischaemic neuronal loss in gerbil hippocampal CA1 by glycineB and AMPA antagonists. Short communication.

Authors:  J W Lazarewicz; R Gadamski; C G Parsons; W Danysz
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

7.  The anticonvulant effect of cooling in comparison to α-lipoic acid: a neurochemical study.

Authors:  Yasser A Khadrawy; Heba S Aboulezz; Nawal A Ahmed; Haitham S Mohammed
Journal:  Neurochem Res       Date:  2013-02-07       Impact factor: 3.996

8.  Heating of the brain to maintain normothermia during ischemia aggravates brain injury in the rat.

Authors:  T Miyazawa; P Bonnekoh; R Widmann; K A Hossmann
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  Attenuation of focal ischemic brain injury in mice deficient in the epsilon1 (NR2A) subunit of NMDA receptor.

Authors:  E Morikawa; H Mori; Y Kiyama; M Mishina; T Asano; T Kirino
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

10.  A selective N-type calcium channel antagonist protects against neuronal loss after global cerebral ischemia.

Authors:  K Valentino; R Newcomb; T Gadbois; T Singh; S Bowersox; S Bitner; A Justice; D Yamashiro; B B Hoffman; R Ciaranello
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.